Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis

Autor: Sehm, Tina, Rauh, Manfred, Wiendieck, Kurt, Buchfelder, Michael, Eyüpoglu, IIker Y., Savaskan, Nicolai E.

Publikováno v: Oncotarget

The glutamate exchanger xCT (SLC7a11) is causally linked with the malignancy grade of brain tumors and represents a key player in glutamate, cystine and glutathione metabolism. Although blocking xCT is not cytotoxic for brain tumors, xCT inhibition d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::32719666b4e387ee8fe3d9afc3d46df8
https://opus4.kobv.de/opus4-fau/files/8830/Sehm_temozolomide.pdf

Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis.

Autor: Sehm T; Translational Cell Biology & Neurooncology Laboratory, Department of Neurosurgery, Universitätsklinikum Erlangen, Medical School of The Friedrich Alexander University of Erlangen-Nürnberg (FAU), Schwabachanlage 6 (Kopfklinik), Germany., Rauh M; Department of Pediatrics and Adolescent Medicine, Universitätsklinikum Erlangen, Medical School of The Friedrich Alexander University of Erlangen-Nürnberg (FAU), Germany., Wiendieck K; Department of Spinal Colum Therapies, Kliniken Dr. Erler, Nürnberg, Germany., Buchfelder M; Translational Cell Biology & Neurooncology Laboratory, Department of Neurosurgery, Universitätsklinikum Erlangen, Medical School of The Friedrich Alexander University of Erlangen-Nürnberg (FAU), Schwabachanlage 6 (Kopfklinik), Germany., Eyüpoglu IY; Translational Cell Biology & Neurooncology Laboratory, Department of Neurosurgery, Universitätsklinikum Erlangen, Medical School of The Friedrich Alexander University of Erlangen-Nürnberg (FAU), Schwabachanlage 6 (Kopfklinik), Germany., Savaskan NE; Translational Cell Biology & Neurooncology Laboratory, Department of Neurosurgery, Universitätsklinikum Erlangen, Medical School of The Friedrich Alexander University of Erlangen-Nürnberg (FAU), Schwabachanlage 6 (Kopfklinik), Germany.; BiMECON Ent. Berlin, Germany.

Publikováno v: Oncotarget [Oncotarget] 2016 Nov 15; Vol. 7 (46), pp. 74630-74647.